UNIVERSAL-PEACE-FED
10.9.2020 11:43:11 CEST | Business Wire | Press release
In an attempt to spread hope and optimism during the coronavirus pandemic which has infected more than 27 million people and killed over 189,000 globally, UPF, an NGO in general consultative status with the Economic and Social Council of the United Nations will convene its first virtual International Leadership Conference (ILC) on Sept. 11-13, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005456/en/
The ILC will host concurrent webinars in three, time-zone friendly clusters: the Americas, Asia Pacific, and the combined continents of Europe, Africa, and the Middle East.
“This year has seen dramatic disruptions, not only due to the COVID-19 pandemic but in geopolitics, the world economy, the media, religion and all levels of society,” said Universal Peace Federation Chairman Dr. Thomas G. Walsh.
“When the world’s leaders and citizens gather and listen to each other,” he added, “it’s easy to envision how our friendships can grow, and how we can live as one global family.”
Former Secretary-General of the United Nations, Mr. Ban Ki-moon said at the recent virtual summit “Rally of Hope”, Aug. 9, 2020, he believed that “UPF will become a cornerstone to build lasting peace around the world.”
In addition to addressing major issues of the day, the conference will commemorate the 15-year anniversary of the Universal Peace Federation and the centenary of UPF’s Co-Founder, Rev. Dr. Sun Myung Moon (1920-2012).
Featured speakers in the Europe, Africa and Middle-East Peace-Dialogue will include former heads of state such as Goodluck Jonathan from Nigeria or H.E Marie-Louise Coleiro Preca from Malta, or Dr. Werner Fasslabend, former minister of defense, Austria, religious leaders with a large following such as Prophet Radebe from South Africa or Cheikh Soufi Bilal Diallo from Mali, and business leaders such as the philanthropist Joseph Busha from Zimbabwe.
The September 11-13 program will highlight the work of UPF’s seven Associations: International Summit Council for Peace (ISCP), International Association of Parliamentarians for Peace (IAPP), Interreligious Association for Peace and Development (IAPD), International Media Association for Peace (IMAP), International Association of Academicians for Peace (IAAP), International Association for Peace and Economic Development (IAED) and International Association of First Ladies for Peace (IAFLP).
Please register for the ILC sessions here: http://www.ilc-2020.org . You will then receive by email an invitation including all the links for each session as well as a brief description of each session. In addition to English, translations will be available in Arabic, French, Portuguese, Spanish and Russian. Attendance is free.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005456/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom